Nutritional composition for reducing blood sugar and blood fat and application thereof

Abstract

The invention discloses a nutritional composition for reducing blood sugar and blood fat and application of the nutritional composition. The invention provides a nutritional composition helpful for maintaining a healthy level of blood fat and / or blood sugar. The nutritional composition comprises the following necessary components: a colostrum component and a beta-glucan component, moreover, in the nutritional composition, the mass ratio of the colostrum component to the beta-glucan component is (200-0.1): (0.1-100). The components in the nutritional composition for reducing blood sugar and blood fat provided by the invention have a synergistic effect, so that the levels of blood sugar and blood fat can be remarkably improved.

Description

Technical Field

[0001] The invention belongs to the field of food, and relates to a nutritional composition, and more specifically, to a nutritional composition for lowering blood sugar and blood lipids and an application thereof. Background Art

[0002] Diabetes and its complications not only cause a double blow to the patient's body and mind, but also bring a heavy burden to the family and threaten life and health. Traditional treatments mostly use diet control, oral hypoglycemic drugs and insulin injections. Although they can control blood sugar, they limit the richness of patients' food intake and bring many inconveniences and pains. At the same time, on the other hand, it is also crucial for people who do not have diabetes (such as healthy people) or other non-therapeutic purposes to maintain a healthy blood sugar level.

[0003] Hyperlipidemia is also a common disease that plagues middle-aged and elderly people. With age, endocrine function declines, and blood lipid levels rise accordingly. The risk of hyperlipidemia in middle-aged and elderly people is much higher than that in young people. It is worth noting that diseases such as diabetes, kidney disease, cholelithiasis, and some drugs (such as hypoglycemic drugs, diuretics, oral contraceptives, etc.) may also cause lipid metabolism disorders and lead to secondary hyperlipidemia. Traditional treatments mostly control blood lipids through oral lipid-lowering drugs and restricted diets, which also limits the diversity of patients' nutritional intake. In addition, the need to maintain healthy levels of blood lipids (cholesterol / triglycerides) for people who do not suffer from hyperlipidemia (such as healthy people) or other non-therapeutic purposes is also very urgent.

[0004] β-glucan is composed of glucose units and is widely found in microorganisms, plants and animals. It is a polysaccharide unit of glucose. Structurally, most of them are linked by β-1,3 bonds. It is a polymer with certain biological activity. In the middle of the 20th century, foreign scholars discovered that there was a substance on the yeast cell wall that enhanced immune function. It was not until more than 20 years later that this active substance was determined to be β-1,3-glucan.

[0005] Yeast glucan is derived from Saccharomyces cerevisiae. Due to its special structure, it has multiple physiological activities. In the United States, the FDA has listed it in GRAS (generally regarded as safe). As a food raw material, it is widely used in various foods. In my country, yeast glucan is also approved as a new resource food, so that it can be used in various foods. As a dietary fiber, yeast glucan can be decomposed by intestinal bacteria, promote gastrointestinal motility, stimulate the secretion of digestive juices, and has the function of assisting digestion; it can increase intestinal motility and promote defecation, thereby effectively preventing constipation; it can increase the absorption of calcium, magnesium and zinc in the human intestine. The unique β-(1→3) skeleton structure of yeast glucan gives it a strong immunomodulatory activity. It can significantly improve human immunity.

[0006] Bovine colostrum contains precious active immunoglobulins (IgG, IgA, IgM, IgE, IgD) and rich milk calcium, protein, various trace elements and other nutrients. Studies have found that bovine colostrum is rich in immunoglobulins, which can directly improve the body's immune ability, supplement the deficiencies of the immune system, reduce the chances of respiratory and gastrointestinal infections, and promote the development of children's brains, bones, and teeth, so that children can thrive and grow up healthily.

[0007] However, it is unclear what effects colostrum and β-glucan combined use have, especially what effects on blood lipids and blood sugar.

[0008] Existing blood sugar and lipid-lowering drugs may bring health side effects. Therefore, the present invention attempts to optimize the proportion and dosage of the composition through cell experiments to find safer and more effective foods, health foods or methods for maintaining healthy levels of blood sugar and blood lipids, so as to maintain healthy levels of blood sugar and blood lipids in healthy people, while ensuring the safety and effectiveness of new measures. Summary of the invention

[0009] Problem that the invention aims to solve

[0010] The prior art and products do not mention the effect of using colostrum and β-glucan combination to reduce blood sugar, especially the ratio is not mentioned in the combination formula. The present invention has optimized the formula combination and ratio through a large number of experiments, and prepared a nutritional composition that maintains healthy blood sugar and / or blood lipid levels (e.g., reduces blood sugar and blood lipid) according to the characteristics of the middle-aged and elderly, meeting the market demand for its functional composition.

[0011] To solve the above problems, the present invention evaluates the effect of colostrum and β-glucan composition on lowering blood sugar and blood lipids through experiments. By scientifically combining colostrum and β-glucan components to make a nutritional composition, abnormal blood sugar and blood lipids can be improved.

[0012] Solutions for solving problems

[0013] [1] A nutritional composition that helps maintain healthy blood lipid and / or blood glucose levels, wherein the nutritional composition comprises the following essential components: a colostrum component and a β-glucan component;

[0014] Furthermore, in the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is (200-0.1):(0.1-100).

[0015] [2] The nutritional composition according to [1], wherein the mass ratio of the colostrum component to the β-glucan component in the nutritional composition is (150-0.5):(0.5-100).

[0016] [3] A nutritional composition according to [1] or [2], wherein the colostrum component comprises colostrum and / or colostrum powder, and optionally, the colostrum is derived from at least one of cows, sheep, horses and camels; and / or the β-glucan component comprises one or more β-glucans derived from plants or fungi.

[0017] [4] The nutritional composition according to any one of [1] to [3], wherein the β-glucan comprises yeast β-glucan.

[0018] [5] A food comprising or using the nutritional composition according to any one of [1] to [4].

[0019] [6] The food according to [5], wherein the food is a nutritional food, a functional food or a health product.

[0020] [7] The food according to [5] or [6], wherein the food comprises pasta, beverages, reconstituted food, baked goods, sauces or functional nutritional supplements.

[0021] [8] Use of a composition containing two essential components, colostrum and β-glucan, in the preparation of a nutritional composition that helps maintain healthy blood lipid and / or blood glucose levels.

[0022] [9] Use of a composition containing two essential components, colostrum and β-glucan, in the preparation of food that helps maintain healthy levels of blood lipids and / or blood sugar.

[0023]

[10] The use according to [8] or [9], wherein the nutritional composition or the food inhibits the activity of α-glucosidase, alleviates insulin resistance, improves insulin sensitivity, restores glucose consumption capacity and / or increases the expression level of the gene PI3K; and / or the nutritional composition or the food reduces lipid deposition in hepatocytes, increases lipoprotein lipase activity and / or increases the expression level of the PPAR-α gene.

[0024] Effects of the Invention

[0025] The inventors unexpectedly found in experiments that the composition of specific composition provided in the present application can be used to improve blood sugar and blood lipid conditions.

[0026] After a large number of experiments, the present invention optimizes the formula combination and proportion to prepare a nutritional composition for improving insulin resistance, lowering blood sugar and blood lipids. Compared with general compositions, the two can synergistically improve and exert the greatest effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1Schematic diagram of the MTT toxicity results of two nutrients on HepG2. DETAILED DESCRIPTION

[0028] Various exemplary embodiments, features and aspects of the present invention will be described in detail below. The word "exemplary" used here means "used as an example, embodiment or illustrative". Any embodiment described here as "exemplary" is not necessarily interpreted as being superior or better than other embodiments.

[0029] In addition, in order to better illustrate the present invention, numerous specific details are provided in the following specific embodiments. It should be understood by those skilled in the art that the present invention can be implemented without certain specific details. In other examples, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present invention.

[0030] Unless otherwise stated, the units used in this specification are all international standard units, and the numerical values ​​and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production.

[0031] In this specification, the word "may" means both performing a certain process and not performing a certain process.

[0032] In this specification, the references to "some specific / preferred embodiments", "other specific / preferred embodiments", "embodiments", etc., mean that the specific elements (e.g., features, structures, properties and / or characteristics) described in connection with the embodiments are included in at least one embodiment described herein, and may or may not exist in other embodiments. In addition, it should be understood that the elements may be combined in various embodiments in any suitable manner.

[0033] In this specification, the numerical range expressed using "a numerical value A to a numerical value B" means a range including the endpoints numerical values ​​A and B.

[0034] In the present invention, the term "about" is used to define the numerical range and parameters of the present invention are approximate values, and the specific relevant values ​​are presented as accurately as possible. Unless otherwise expressly stated, it should be understood that all ranges, quantities, values ​​and percentages used in the present invention are modified by "about". Here, "about" usually means that the actual value is within ±3%, ±2%, ±1% or ±0.5% of a particular value or range.

[0035] In the present specification, a numerical range expressed using "above" or "below" means a numerical range including the number.

[0036] In this specification, the word "may" means both performing a certain process and not performing a certain process.

[0037] In this specification, the use of "optional" or "optional" indicates that certain substances, components, execution steps, application conditions and other factors are used or not used.

[0038] In the present invention, "infant" is used to refer to a human group of 0 to 6 months old.

[0039] In the present invention, "older infants" are used to refer to a human group of 6 to 12 months of age.

[0040] In the present invention, the term "infant" is used to refer to a human group of 12 to 36 months old.

[0041] In the present invention, "infants" are used to refer to a human group under the age of 3.

[0042] In the present invention, the term "children" used herein refers to a human living group that is older than 3 years old and younger than 12 years old and is in the growth and development stage.

[0043] In this specification, the term "adult" refers to a person over the age of 18 years.

[0044] In this specification, the term "youth" refers to people aged 7-40 years old.

[0045] In this specification, the term "middle-aged people" refers to people aged 41-65 years old.

[0046] In this specification, the term "elderly" or "elderly person" refers to a person over the age of 65 years.

[0047] <First aspect>

[0048] In a first aspect of the present invention, a nutritional composition is provided, the nutritional composition comprising the following essential components: a colostrum component and a β-glucan component, wherein the mass ratio of the colostrum component to the β-glucan component is (200-0.1):(0.1-100). The nutritional composition exhibits a significant synergistic effect, significantly controls and effectively maintains healthy blood sugar and / or blood lipid levels, such as reducing the blood sugar level and blood lipid content of the human body.

[0049] Compared with colostrum and β-glucan alone, the nutritional composition provided by the present invention can synergistically maintain healthy blood sugar and / or blood lipid levels, such as reducing blood sugar levels and blood lipid content in the human body. When the mass ratio of colostrum and β-glucan is within the above range, the relevant effect is particularly prominent.

[0050] The technical solution of the present invention is mainly obtained based on the following insights:

[0051] The present invention first verifies the safe dosage range of colostrum and β-glucan from a (cell) biological perspective, and within this range, studies the biological performance of the two separately and in different proportions. As a result, it is unexpectedly discovered that the combination of colostrum and β-glucan, especially in a specific ratio, can produce an obvious synergistic effect in maintaining healthy levels of blood sugar and / or blood lipids, such as lowering blood sugar and blood lipids in the human body.

[0052] (Colostrum components)

[0053] In the present invention, the colostrum component includes colostrum and / or colostrum powder, and the colostrum refers to the milk secreted within 72 hours after the birth of a healthy animal or prepared into a powder. There is no particular limitation on the source of the colostrum of the present invention in principle. In some embodiments, the colostrum can be bovine colostrum, sheep colostrum, camel colostrum, horse colostrum, etc.

[0054] In some embodiments, the colostrum may preferably be bovine colostrum.

[0055] In some embodiments, the bovine colostrum is milk from a cow within about 3 days after calving, or a raw material made from milk by low-temperature spray drying or freeze drying. When bovine colostrum is used in combination with β-glucan, the nutritional composition achieves a better synergistic effect of maintaining healthy blood sugar and / or blood lipid levels, such as reducing blood sugar and blood lipids in the human body.

[0056] (β-Glucan fraction)

[0057] Beta-glucan (abbreviated as β-glucan) belongs to fiber polysaccharides (complex sugars). Structurally, most of them are polymers linked by β-1,3 bonds and can be derived from a variety of microorganisms, animals or plants.

[0058] There is no particular limitation on the specific source of β-glucan in the present invention. The sources of β-glucan applicable to the present invention include yeast, oats, barley, fungi (mushrooms), algae, etc., or a mixture thereof. Further specific examples include oat β-glucan, kelp β-glucan, thermogel β-glucan, golden algae β-glucan, shiitake β-glucan, lichen β-glucan, oyster mushroom β-glucan, yeast polysaccharide, black fungus β-glucan, and barley polysaccharide.

[0059] In some embodiments of the present invention, as the β-glucan component, one of β-glucans from yeast, oats, and barley or a mixture thereof can be used, preferably, the β-glucan is selected from yeast β-glucan.

[0060] In some embodiments of the present invention, for the β-glucan component, raw materials such as plants and fungi containing this component can be used to provide a certain content of β-glucan in the final composition. In addition, preferably, the β-glucan active ingredient with higher purity extracted from these raw materials can also be directly used.

[0061] Furthermore, there is no particular limitation on the usage of the extracted β-glucan, and the β-glucan may be used in the form of a solution or an emulsion.

[0062] (Synergy)

[0063] In order to obtain better synergistic effects in maintaining healthy blood sugar and / or blood lipid levels, such as lowering the blood sugar level and blood lipid content of the human body, in some embodiments, in the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is (180-0.2):(0.2-100).

[0064] In some preferred embodiments, in the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is (150-0.5):(0.5-100).

[0065] In order to obtain further better synergistic effects in maintaining healthy blood sugar and / or blood lipid levels, such as lowering blood sugar and blood lipids, in some more preferred embodiments, in the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is (100-0.5):(0.5-50). In some further preferred embodiments, in the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is (100-1):(0.5-20), and more preferably the mass ratio is (100-1):(1-10), (100-1):(1-7), (100-1):(1-5), (100-1):(1-3), (80-1):(1-10), (70-1):(1-10), (60-1):(1-10), (50-1):(1-10), (40-1):(1-10), (30-1):(1-10), (20-1):(1-10), or (10-1):(1-10).

[0066] In some exemplary embodiments, in the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is 100:1; 50:1; 10:1; 5:1; 1:1; 1:2 or 1:10.

[0067] When the forest milk and β-glucan are within the above range, the composition further obtains a better synergistic effect of maintaining healthy blood sugar and blood lipid levels, such as reducing the blood sugar level and blood lipid content of the human body. It can produce a significant synergistic effect in reducing blood sugar and blood lipid in the human body.

[0068] In the present invention, the combination of colostrum and β-glucan unexpectedly found a synergistic effect in maintaining healthy blood sugar and blood lipid levels. In addition, it was also found that under the same conditions and proportions, the synergistic effect can also achieve the effect of regulating blood sugar and blood lipids when using relatively low concentrations of colostrum and β-glucan.

[0069] (Composition)

[0070] The nutritional composition of the present invention comprises at least the colostrum component and the β-glucan component described above. There is no particular limitation on the method of forming the composition, which can be prepared by mixing the above-mentioned components in a solvent or by mixing two high-purity extracts.

[0071] In addition, there are no particular limitations on other components that may be used in the composition of the present invention. Without impairing the effects of the present invention, other edible ingredients, food additives or solvent components commonly used in the art may be used.

[0072] The nutritional composition of the present invention may be in a liquid form, or may be in a semi-solid form or a solid form.

[0073] When the nutritional composition of the present invention is in liquid form, in some preferred embodiments, in the nutritional composition, the concentration of colostrum is 0-5 mg / mL, and the concentration of β-glucan is below 2.0 mg / mL. The two can synergistically enhance and significantly reduce the blood sugar level and blood lipid content of the human body.

[0074] In some more preferred embodiments, in the nutritional composition, the concentration of colostrum is 0-2 mg / mL, and the concentration of β-glucan is less than 1.5 mg / mL. In some further preferred embodiments, in the nutritional composition, the concentration of colostrum is 0-1.5 mg / mL, and the concentration of β-glucan is less than 1.5 mg / mL, more preferably, the concentration of colostrum is 10 μg / mL-1 mg / mL, and the concentration of β-glucan is 10 μg / mL-1 mg / mL, for example: the concentration of colostrum is 10 μg / mL; 100 μg / mL; 500 μg / mL; 1000 μg / mL, and the concentration of β-glucan is 10 μg / mL; 100 μg / mL; 1000 μg / mL.

[0075] (use)

[0076] Furthermore, the above-mentioned composition of the present invention has been verified by experiments to improve the effects of PA-induced insulin resistance and OA-induced lipid deposition, indicating that the composition can reduce PA-induced insulin resistance and OA-induced lipid deposition, and thus can have a more obvious effect of regulating blood sugar and blood lipids. In some specific embodiments, the blood sugar and blood lipid regulation is a non-therapeutic purpose. Therefore, it can be used as a food, a functional health product or a functional health supplement.

[0077] <Second Aspect>

[0078] In a second aspect of the present invention, a food is provided, wherein the food comprises or uses the nutritional composition described in the first aspect.

[0079] The food of the present invention can be a food suitable for maintaining healthy blood sugar levels (e.g., controlling blood sugar) and / or maintaining healthy blood lipid levels (e.g., lowering blood lipids) for healthy people, diabetics and / or patients with dyslipidemia such as hyperlipidemia.

[0080] In some specific embodiments, the food can be obtained by processing the nutritional composition described according to the first aspect above.

[0081] There is no particular limitation on the food of the present invention, and the food may generally be pasta, beverages, reconstituted food, baked goods, sauces or functional nutritional supplements.

[0082] Wheaten food may include staple foods processed or made from flour-based raw materials, coarse grain staple foods, etc., such as steamed bread, cakes, noodles, stuffed staple foods, etc.

[0083] For baked pastries, it can be baked cakes or biscuits mainly based on cream, eggs and baking powder.

[0084] There are no particular restrictions on beverages, which may be fruit drinks, vegetable drinks, milk tea drinks, tea drinks, milk, yogurt, vitamin drinks, etc. For fruit or vegetable drinks, in addition to the two functional components of the present invention, they may also include fruit or vegetable juice, or their solid components, etc. For vitamin drinks, in addition to the two functional components of the present invention, they may also mainly include various functional vitamins and other functional ingredients, such as white sugar, sodium cyclamate, acesulfame potassium, taurine, potassium sorbate, lysine, inositol, vitamin pp, vitamin B6, vitamin B12, citric acid, etc.

[0085] Reconstituted foods may typically be reconstituted milk powder products, such as adult milk powder, middle-aged and elderly milk powder, and the like.

[0086] In addition, there are no special restrictions on functional nutritional supplement foods, which can be used as nutritional supplements or meal replacements. Such foods, in addition to the two components of the present invention, may also include one or more of the following components: plant product ingredients, animal dairy product ingredients, animal meat product ingredients, protein ingredients, vitamin supplements, mineral supplements, nucleotide supplements, polyunsaturated fatty acid supplements and any food-acceptable excipients.

[0087] Plants or plant extracts, including fruits such as figs, pomegranates, kiwis, tangerines, oranges, pineapples, strawberries, apples, rubber, grapes, pears, cherries, blueberries, blackberries, blackcurrants, cranberries, raspberries, melons, emblica chinensis and bilberry or their extracts; fruit and vegetable substances such as onions, cucumbers, tomatoes, cauliflower, carrots, spinach, kale, Brussels sprouts, garlic, basil, oregano or their extracts; grains such as rice (indica rice, japonica rice, glutinous rice), wheat (wheat, barley, oats, rye), corn, sorghum, millet, sorghum, yellow rice, buckwheat, soybeans, broad beans, peas, mung beans, red beans, kidney beans or their extracts; nuts such as walnuts, pistachios, cashews, hazelnuts, almonds, apricots, pine nuts, peanuts, melon seeds, chestnuts, macadamia nuts, ginkgo nuts or their extracts; coffee or its extracts.

[0088] Animal ingredients include meat products from beef, lamb, fish or poultry.

[0089] The fat component may include at least one of saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, OPO structured lipids, DHA, EPA, ARA, and phospholipids. More specifically, the fat includes safflower seed oil, walnut oil, peanut oil, corn oil, soybean oil, argan oil, olive oil, tea oil, sacha inchi oil, olive oil, coconut oil, perilla oil, deep-sea fish oil, cocoa butter, palm oil, butter, cream, lard, medium-chain triglycerides or lecithin, etc.

[0090] Functional added components include vitamins (one or more of vitamin A, β-carotene, vitamin D3, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, pantothenic acid, folic acid, niacin, choline, inositol, biotin), starch, modified starch, amino acids (L-lysine-L-glutamic acid, L-glutamic acid, L-arginine, L-tryptophan, L-glutamine, taurine, L-valine, L-isoleucine or L-leucine, etc.), traditional Chinese medicine or traditional Chinese medicine extracts, dietary fiber (inulin, konjac flour, galacto-oligosaccharides, fructo-oligosaccharides, isomalto-oligosaccharides, soybean polysaccharides, cyclodextrin, resistant dextrin or soybean fiber, etc.).

[0091] The protein component is selected from at least one of whey protein powder, soy protein isolate, whole milk powder, whole egg powder, lactoferrin, bovine colostrum, amino acids, and protein peptides; and the amino acids are selected from at least one of L-lysine, L-glutamic acid, L-glutamic acid, L-arginine, L-tryptophan, L-glutamine, taurine, L-valine, L-isoleucine, and L-leucine; the protein peptides are selected from one or more of soy oligopeptides, wheat protein peptides, silkworm pupa protein peptides, marine fish oligopeptide powder, kola peptides, amino peptides, and ovalbumin peptides.

[0092] Trace element supplements may include metal ion salts of organic acids, such as one or more of calcium citrate, L-calcium lactate, calcium hydrogen phosphate, potassium gluconate, sodium citrate, ferrous gluconate, potassium iodide, zinc gluconate, sodium selenite, copper gluconate, chromium sulfate, manganese gluconate and magnesium gluconate.

[0093] Any food-acceptable excipients, including but not limited to solvents, antioxidants, antibacterial agents, thickeners, diluents, cosolvents, stabilizers, emulsifiers, fillers, disintegrants, lubricants, coating materials, anti-caking agents, flavoring agents, sweeteners, edible flavors, edible colorings, etc.

[0094] The specific form of the nutritional / health food of the present invention is not particularly limited, and may be solid (powder or block, etc.), semi-solid (soft, paste or thick, etc.) or liquid.

[0095] The present invention does not specifically limit the food that can be prepared using the above nutritional composition and has the effect of maintaining healthy blood sugar and / or blood lipid levels, such as reducing human blood sugar levels and blood lipid content. In some embodiments, the food is a solid dairy product or a liquid dairy product; for example, milk powder, cheese, yogurt, liquid milk, etc.

[0096] In some specific embodiments, the nutritional or health food can be a powdered reconstituted food (solid beverages, milk powder, instant coffee, cereal powder, nut powder or lotus root powder, etc.), a liquid beverage (carbonated beverages, fruit and vegetable juice beverages, functional beverages, tea beverages, milk beverages or alcoholic beverages, etc.).

[0097] Typically, the above-mentioned foods include: milk powder for pregnant women, milk powder for middle-aged and elderly people, or nutritional or dietary supplements, etc.

[0098] <Third Aspect>

[0099] The present invention also provides the use of a composition containing two essential components, colostrum and β-glucan, in preparing a nutritional composition that helps maintain healthy blood lipid and / or blood sugar levels. The present invention also provides the use of a composition containing two essential components, colostrum and β-glucan, in preparing a food that helps maintain healthy blood lipid and / or blood sugar levels.

[0100] In some embodiments, the nutritional composition or food product is effective in maintaining healthy blood glucose and / or blood lipid levels, such as lowering blood glucose levels and / or lowering blood lipid levels.

[0101] In some embodiments, maintaining healthy blood lipid and / or blood glucose levels is a non-therapeutic purpose of maintaining healthy blood lipid and / or blood glucose levels, that is, the composition containing the two essential components of colostrum and β-glucan is not used for abnormal blood lipid or blood glucose caused by diseases (such as diabetes, hyperlipidemia, etc.).

[0102] In some specific embodiments, maintaining healthy blood sugar levels, such as lowering blood sugar levels, includes inhibiting the activity of α-glucosidase, alleviating insulin resistance, improving insulin sensitivity, restoring glucose consumption capacity and / or increasing the expression of the gene PI3K.

[0103] In some specific embodiments, maintaining healthy blood lipid levels, for example, lowering blood lipid levels includes reducing lipid deposition in hepatocytes, increasing lipoprotein lipase activity, and / or increasing PPAR-α gene expression.

[0104] In some embodiments, the specific selection and ratio of the colostrum and β-glucan are as described above in <First Aspect>.

[0105] Example

[0106] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.

[0107] raw material

[0108] In the following Examples section, unless otherwise stated, the starting materials used were as follows.

[0109] Bovine colostrum: INGREDTA, U22425;

[0110] Yeast β-glucan: Angel Yeast Co., Ltd., 2023070201.

[0111] In the following sections, unless otherwise specified, when referring to the parts by mass and ratios of the ingredients in the nutritional composition, the ratios refer to the mass ratios of bovine colostrum and yeast β-glucan.

[0112] Experimental methods

[0113] 1. Experimental Materials

[0114] The experimental materials are shown in Table 1.

[0115] Table 1: Main reagents for the experiment

[0116]

[0117]

[0118] 2. Experimental Equipment

[0119] The experimental equipment is shown in Table 2.

[0120] Table 2: Main instruments and equipment for the experiment

[0121]

[0122]

[0123] 3. Cell Experiment

[0124] 1. HepG2 cell culture

[0125] HepG2 cells were placed in DMEM complete medium containing 10% FBS, cultured in a cell culture incubator at 37°C and 5% CO2 saturated humidity, and the medium was changed every other day. Cells can be subcultured when the confluence is greater than 85% during the logarithmic growth phase, washed twice with PBS, digested with 0.25% trypsin for 2 minutes, and then complete medium was added to terminate digestion. The cells were blown away from the bottle wall and transferred to a centrifuge tube. Centrifuged at 1500rpm for 5 minutes, the supernatant was removed and subcultured at a ratio of 1:2. Cells in the logarithmic growth phase were taken for the experiment.

[0126] 2. Construction of HepG2 cell model

[0127] (1) Construction of HepG2 cell hyperlipidemia model

[0128] HepG2 cells were placed in a 24-well culture plate and in a low-glucose DMEM complete medium containing 10% FBS, and cultured in a cell culture incubator at 37°C and 5% CO2 saturated humidity until the number reached 90%. After becoming adherent cells, they were replaced with a high-glucose DMEM complete medium containing 10% FBS. The test substance was intervened in the cells for 4 hours in advance, and then 0.3mM sodium oleate (OA) was added for treatment for 16 hours. After 16 hours, the high-lipid modeling of the cells was completed, and the cells could be collected for testing of different indicators.

[0129] (2) Construction of HepG2 cell insulin resistance model

[0130] HepG2 cells were placed in a 24-well culture plate and low-glucose DMEM complete medium containing 10% FBS, and cultured in a 37°C, 5% CO2 saturated humidity cell culture incubator until the number reached 90%. After becoming adherent cells, they were replaced with serum-free high-glucose DMEM medium for starvation operation for 12 hours, and the supernatant was discarded again. After replacing with new serum-free high-glucose DMEM medium, the test substance was intervened in the cells for 4 hours in advance, and then 0.3mM palmitate (PA) was added for treatment for 24 hours. After 24 hours, the high-glucose modeling of the cells was completed, and the cells could be collected for testing of different indicators.

[0131] 3. MTT cell activity assay

[0132] HepG2 cells were digested with trypsin to prepare single-cell suspension, and 200 μL / well of the cell suspension was inoculated into 96-well flat-bottom culture plates (3×10 4 cells / well), incubated at 37°C, 5% CO2 environment, after the cells are completely attached, the culture medium is discarded, the cells are washed 1-2 times with PBS buffer, 20 μL / well of culture medium of bovine colostrum (0-4.0 mg / mL) and / or yeast β-glucan (0-4.0 mg / mL) of different mass concentrations of the samples to be tested are added, 3 wells are duplicated in each group, and a blank control group (normal HepG2 cell culture without the sample to be tested) is set up for culturing in a 37°C, 5% CO2 incubator for 12 hours, the original culture medium is discarded, 20 μL / well of MTT solution with a mass concentration of 5 g / L is added in the dark, the MTT solution is discarded after culturing for 4 hours, 150 μL DMSO is added, the plate is fully vibrated for 10 minutes on an enzyme-labeled analyzer, the purple precipitate is dissolved and the absorbance is measured at 490 nm to monitor cell activity and screen the optimal safe concentration of the monomer test substance.

[0133] The cell survival rate (C) was calculated according to formula (1): C = X1 / X0 × 100%

[0134] (1) Where: X1 represents the optical density (OD) value of the sample group; X0 represents the OD value of the blank control group.

[0135] 4. Cell Viability Detection

[0136] Prepare a single cell suspension of HepG2 hepatocytes by placing approximately 1×10 4Cells were inoculated in a 96-well plate and cultured until the cells occupied about 85% of the wells, and the sample to be tested was intervened (performed according to the nutrient combination and dose determined in the 2MTT cell activity assay in step 3). After 12 hours of intervention with the sample to be tested, 10 μL of CCK8 solution was added to each well of the plate using a pipette. After incubation in a 37°C constant temperature incubator for 4 hours, the absorbance at 450 nm was measured using a microplate reader.

[0137] IV. Blood sugar lowering cell experiment

[0138] (I) In vitro α-glucosidase inhibitory activity test

[0139] Thoroughly mix 20 μL of the test solution (the concentration of each test substance determined by the CCK8 experiment in the 3 cell viability assay in step 3) with 20 μL of α-glucosidase solution (0.3 U / mL) and 140 μL of PBS buffer (0.2 M), react at 37°C for 20 min, add 20 μL of 3 mmol / L pNPG solution, react at 37°C for 15 min, add 80 μL of Na2CO3 solution (0.5 mol / L) to terminate the reaction, and use acarbose as the positive control. The method used for the positive control is consistent with the above-mentioned test substance method, and the test substance solution is replaced with 10 μg / mL acarbose solution.

[0140] The α-glucosidase inhibition rate was calculated according to the following formula:

[0141] α-Glucosidase inhibition rate = [1–(B1–B2) / (B3–B4)] × 100%

[0142] Where: B1 is the absorbance of the sample group;

[0143] B2 is the absorbance of the sample background group;

[0144] B3 is the absorbance of the blank group;

[0145] B4 is the absorbance of the blank background group.

[0146] (II) Preparation of long-chain fatty acid esters

[0147] Sodium palmitate was dissolved in 6 mL of high-glucose DMEM and heated in a 75°C water bath until completely dissolved. When the solution temperature dropped to about 50°C, an equal volume of 10% (w / v) BSA was added for conjugation dissolution. After ultrasonication for 10 min, oscillation and mixing were performed for 10 min to allow the fatty acid to completely combine with BSA to form fatty acid-BSA (prepared concentration: 10 mmol / L). The fatty acid ester was filtered and sterilized using a 0.22 μm filter membrane for later use.

[0148] (III) Cellular glucose consumption detection

[0149] HepG2 cells were placed in a 24-well culture plate and low-glucose DMEM complete medium containing 10% FBS, and cultured in a cell culture incubator at 37°C and 5% CO2 saturated humidity until the number reached 90%. After becoming adherent cells, the medium was replaced with serum-free high-glucose DMEM medium for starvation for 12 hours, and the supernatant was discarded again. After replacing with new serum-free high-glucose DMEM medium, the sample to be tested was intervened in the cells for 4 hours in advance, and then 0.3mM palmitate was added for 24 hours. The supernatant of the culture fluid was aspirated, and the glucose content in the supernatant of the culture fluid was measured to reflect the glucose consumption. The measurement was performed according to the instructions of the kit, and the glucose consumption was used to feedback the degree of insulin resistance of the cells. The lower the glucose consumption, the more aggravated the insulin resistance, and the higher the glucose consumption, the less insulin resistance.

[0150] (IV) Real-time quantitative polymerase chain reaction (qRT-PCR)

[0151] After analyzing and treating insulin-resistant HepG2 cells, RNA was extracted and reverse transcribed into cDNA using a total RNA extraction kit. Primers were synthesized for PI3K. Fluorescence was detected by qRT-PCR using a kit, and mRNA levels were normalized to GAPDH expression.

[0152] 1. RNA Extraction

[0153] (1) After the cells are taken out from -80℃, add 350μL of lysis buffer RLA and 10μL of proteinase K, vortex and mix until the cells are loose, and let stand at room temperature for 5 minutes. The sample becomes viscous, indicating that the lysis is complete.

[0154] (2) Transfer the cell lysate to the gDNA removal column and centrifuge at 12,000 g for 5 minutes until all the liquid flows out into the collection tube below. If a small amount of liquid remains, centrifuge again.

[0155] (3) Add an equal volume of 70% ethanol to the collection tube from the previous step, mix well, transfer to the RNA adsorption column, centrifuge at 12,000 g for 1 minute, and discard the effluent.

[0156] (4) Add 700 μL of deproteinized solution RW3 to the RNA adsorption column, centrifuge at 12,000 g for 1 min, and discard the effluent; add 500 μL of rinse solution RW to the RNA adsorption column, centrifuge at 12,000 g for 1 min, and discard the effluent; add 500 μL of RW to the RNA adsorption column again, centrifuge at 12,000 g for 1 min, and discard the effluent; put the RNA adsorption column back into the centrifuge, centrifuge at 12,000 g for 2 minutes, and open the lid to dry.

[0157] (5) Add 70 μL of RNase-free water to the RNA adsorption column and transfer it to a new EP tube. After standing at room temperature for 1 minute, centrifuge at 12,000 g for 1 minute and collect the eluate, which is the RNA solution.

[0158] (6) Add 99 μL ddH2O and 1 μL RNA solution to a 96-well plate and measure the absorbance at 260 nm using a microplate reader.

[0159] 2.RT Reverse Transcription

[0160] (1) gDNA removal

[0161] The system configuration is as follows:

[0162]

[0163] The PCR instrument program is as follows:

[0164]

[0165] (2) Reverse transcription

[0166] The system configuration is as follows:

[0167]

[0168] The PCR instrument program is as follows:

[0169]

[0170] (3) cDNA storage

[0171] Place the product from the previous step on ice temporarily. For long-term storage, store it at -20℃ or -80℃.

[0172] 3. qPCR Quantification

[0173] (1) Primer sequence

[0174]

[0175] (2) Prepare the following qPCR reaction system using cDNA as template:

[0176]

[0177] After preparation, mix well, centrifuge, add to the 96-well Roche fluorescent quantitative PCR plate, and then put it into the fluorescent quantitative PCR instrument for reaction;

[0178] (3) qPCR reaction procedure:

[0179] Two-step method

[0180]

[0181]

[0182] Melting curve program:

[0183] (4) Three replicate wells were prepared for each sample, and the relative expression level of the corresponding sample was calculated using the 2^(-△△CT) method.

[0184] 5. Lipid-lowering Cell Experiment

[0185] (I) Preparation of long-chain fatty acid esters

[0186] Sodium oleate was dissolved in 6 mL of high-glucose DMEM and heated in a 75°C water bath until completely dissolved. When the solution temperature dropped to about 50°C, an equal volume of 10% (w / v) BSA was added for conjugation dissolution. After ultrasonication for 10 min, oscillation and mixing were performed for 10 min to allow the fatty acid to completely combine with BSA to form fatty acid-BSA (preparation concentration: 10 mmol / L). The fatty acid ester was filtered and sterilized using a 0.22 μm filter membrane for later use.

[0187] (II) Determination of triglyceride content

[0188] HepG2 cells were placed in a 24-well culture plate and in a low-glucose DMEM complete medium containing 10% FBS, and cultured in a cell culture incubator at 37°C and 5% CO2 saturated humidity until the number reached 90%. After becoming adherent cells, they were replaced with a high-glucose DMEM complete medium containing 10% FBS. The samples to be tested were intervened in the cells for 4 hours in advance, and then 0.3mM sodium oleate was added for 16 hours. After the intervention, the culture medium was discarded, the cells were washed twice with PBS solution, and the PBS was discarded. Triglyceride lysis solution was added to break the cells, and the triglyceride content was measured according to the instructions.

[0189] (III) Lipoprotein lipase (LPL) activity detection

[0190] HepG2 cells were placed in a 24-well culture plate and in a low-glucose DMEM complete medium containing 10% FBS, and cultured in a cell culture incubator at 37°C and 5% CO2 saturated humidity until the number reached 90%. After becoming adherent cells, they were replaced with a high-glucose DMEM complete medium containing 10% FBS. The samples to be tested were intervened in the cells for 4 hours in advance, and then 0.3mM sodium oleate was added for 16 hours. After the intervention, the culture medium was discarded, the cells were washed twice with PBS solution, and the PBS was discarded. Then, the LPL kit was used for detection according to the instructions.

[0191] (IV) Real-time quantitative polymerase chain reaction (qRT-PCR)

[0192] After the intervention of the test sample was completed, RNA was extracted and reverse transcribed into cDNA. Primers were synthesized for PPAR-α. qRT-PCR was performed using a kit to detect fluorescence, and mRNA levels were normalized to GAPDH expression.

[0193] 1. RNA Extraction

[0194] (1) After the cells were taken out from -80°C, 350 μL of lysis buffer RLA and 10 μL of proteinase K were added.

[0195] (Proteinase K), vortex to mix until cells are loose, and let stand at room temperature for 5 minutes. The sample becomes viscous, indicating that lysis is complete.

[0196] (2) Transfer the cell lysate to the gDNA removal column and centrifuge at 12,000 g for 5 minutes until all the liquid flows out into the collection tube below. If a small amount of liquid remains, centrifuge again.

[0197] (3) Add an equal volume of 70% ethanol to the collection tube from the previous step, mix well, transfer to the RNA adsorption column, centrifuge at 12,000 g for 1 minute, and discard the effluent.

[0198] (4) Add 700 μL of deproteinized solution RW3 to the RNA adsorption column, centrifuge at 12,000 g for 1 min, and discard the effluent; add 500 μL of rinse solution RW to the RNA adsorption column, centrifuge at 12,000 g for 1 min, and discard the effluent; add 500 μL of RW to the RNA adsorption column again, centrifuge at 12,000 g for 1 min, and discard the effluent; put the RNA adsorption column back into the centrifuge, centrifuge at 12,000 g for 2 minutes, and open the lid to dry.

[0199] (5) Add 70 μL RNase-free water to the RNA adsorption column and transfer it to a new EP tube.

[0200] After standing at room temperature for 1 minute, centrifuge at 12000g for 1 minute and collect the eluate, which is the RNA solution. (6) Add 99 μL ddH2O and 1 μL RNA solution to the 96-well plate and measure the absorbance at 260 nm with an ELISA reader.

[0201] 2.RT Reverse Transcription

[0202] (1) gDNA removal

[0203] The system configuration is as follows:

[0204]

[0205] The PCR instrument program is as follows:

[0206]

[0207] (2) Reverse transcription

[0208] The system configuration is as follows:

[0209]

[0210] The PCR instrument program is as follows:

[0211]

[0212] (3) cDNA storage

[0213] Place the product from the previous step on ice temporarily. For long-term storage, store it at -20℃ or -80℃.

[0214] 3. qPCR reaction

[0215] (1) Primer sequence

[0216]

[0217] (2) Prepare the following qPCR reaction system using cDNA as template:

[0218]

[0219] After preparation, mix well, centrifuge, add to the 96-well Roche fluorescent quantitative PCR plate, and then put it into the fluorescent quantitative PCR instrument for reaction;

[0220] (3) qPCR reaction procedure:

[0221] Two-step method

[0222]

[0223] Melting curve program:

[0224]

[0225] (4) Three replicate wells were prepared for each sample, and the relative expression level of the corresponding sample was calculated using the 2^(-△△CT) method.

[0226] VI. Experimental dose

[0227] According to the experimental requirements, the cell experiment example was determined, and the specific combination and dosage arrangement are shown in Table 3 below:

[0228] Table 3: Cell experiment dosage

[0229]

[0230] “—” means that it is not added or there is no proportional relationship.

[0231] The OA model is a HepG2 cell hyperlipidemia model induced by oleic acid to accumulate triglycerides;

[0232] The PA model is an insulin resistance model constructed by inducing HepG2 cells with palmitate.

[0233] In the present specification, the above-mentioned model is used to simulate abnormal blood sugar and blood lipids, and the abnormalities include abnormalities that do not reach the disease state.

[0234] 7. Statistical Analysis

[0235] The results are expressed as mean ± standard deviation (n = 3), and SPSS software was used for One-way ANOVA test. When p < 0.05, it was judged to be significantly different, when p < 0.01, it was judged to be extremely significantly different, and when p < 0.001, it was extremely significantly different. In the following text, "*" is also used to indicate P < 0.05, "**" is used to indicate P < 0.01, and "***" is used to indicate P < 0.001.

[0236] Test Case

[0237] Test Example 1: Screening of safe doses of each sample for HepG2 cells

[0238] This test case mainly investigated the MTT toxicity of two initial nutrients to HepG2, including bovine colostrum and yeast β-glucan. The experimental results are as follows Figure 1 As shown:

[0239] Depend on Figure 1 Based on the data in , and combined with specific experimental operations, we can see that:

[0240] (1) Bovine colostrum did not show obvious MTT toxicity within the range of investigation.

[0241] (2) The MTT safety range of yeast β-glucan is below 2.0 mg / mL (based on cell survival rate not less than 80%).

[0242] Test Example 2: Effects of each sample on CCK8 cell viability

[0243] After the dosage groups were determined, the CCK8 kit was used to first investigate the effects of different dosage groups on the cell viability of HepG2 cells. The data on the effects on cell viability are shown in Table 4.

[0244] Table 4: Effects of various examples on HepG2 cell viability

[0245]

[0246] aThe drug used in the OA positive control group was simvastatin (0.03 mM)

[0247] b The drug used in the PA positive control group was metformin (0.05mM)

[0248] “—” means that it is not added or there is no proportional relationship.

[0249] According to the analysis of the experimental data results (Table 4), compared with the blank control group, the cell viability of the OA model control group, the PA model control group and the positive drug intervention group (OA positive control group, PA positive control group) did not show significant fluctuations, which shows that the constructed OA and PA models and their positive drugs have good biosafety. At the same time, the effects of each embodiment on the viability of HepG2 cells were investigated, and no significant adverse effects were found, and the cell viability was maintained above 90%.

[0250] Test Example 3: Effects of each sample on lowering blood sugar and results

[0251] 1. Inhibition rate of α-glucosidase by the nutritional composition

[0252] After confirming the biosafety of each group of examples, the insulin resistance model was constructed by inducing HepG2 cells with palmitate, and the inhibitory activity of the examples on α-glucosidase in vitro was first investigated. The inhibition data of bovine colostrum, yeast β-glucan and the nutritional composition thereof are shown in Table 5.

[0253] Table 5: Inhibition rate data of bovine colostrum, yeast β-glucan and their nutritional composition on α-glucosidase

[0254]

[0255] “—” means that it is not added or there is no proportional relationship.

[0256] The experimental results show (Table 5) that bovine colostrum alone has no significant inhibitory effect on α-glucosidase, yeast β-glucan has a certain inhibitory effect on α-glucosidase, and the inhibitory effect of low-concentration glucan is more obvious. In addition, the inventors surprisingly found that when bovine colostrum and yeast β-glucan are used in combination, there is a synergistic effect on the inhibition of α-glucosidase activity. In particular, according to cell experiment examples 1-8, it can be seen that the inhibition rate of the nutritional complex of the two on α-glucosidase is greater than the sum of the inhibition rates of the two.

[0257] 2. Determination of Glucose Consumption in Cell Model

[0258] The insulin resistance model was constructed by inducing HepG2 cells with palmitate. Compared with the blank control group, the formation of insulin resistance in the model group resulted in a decrease in the consumption of glucose in the supernatant by the cells. In order to evaluate the mitigating effect of nutrients and their compositions on the insulin resistance model, this test case used a pretreatment method of early intervention to exemplarily examine the effects of these substances on improving insulin sensitivity and restoring glucose consumption capacity, and the metformin-treated group was used as a positive control group.

[0259] The glucose consumption in the supernatant of bovine colostrum, yeast β-glucan and the nutritional composition thereof is shown in Table 6.

[0260] Table 6: Data on glucose consumption in the supernatant of bovine colostrum, yeast β-glucan and their nutritional composition

[0261]

[0262] Wherein, “—” indicates no addition or no proportional relationship, and “***” indicates P < 0.001.

[0263] Insulin resistance will cause the rate at which cells consume glucose to decrease. The degree of cellular insulin resistance can be reflected by detecting the amount of cellular glucose consumption. If the glucose consumption is low, the degree of cellular insulin resistance is high, and if the glucose consumption is high, the degree of insulin resistance is low.

[0264] As shown in Table 6, the exemplary bovine colostrum and yeast β-glucan nutritional composition has an alleviating effect on the insulin resistance pattern. In terms of the components and dosages used, Example 6 is equivalent to the combination of cell experiment comparative examples 3 and 5. Relative to the model control group, comparative examples 3 and 5 increased glucose consumption by 0.05 and 2.77, while cell experiment example 6 increased glucose consumption by 3.00, which is greater than the sum of the first two, 2.82.

[0265] 3. Analysis of PI3K gene expression

[0266] PI3K (phosphatidylinositol-3-kinase) is a key component of the insulin signaling pathway, and they play a vital role in insulin sensitization and metabolic homeostasis regulation. In the insulin resistance (IR) HepG2 cell model, decreased activity or impaired function of the PI3K signaling pathway is often observed. This test case aims to explore the mechanism of action of a specific nutritional composition in IR-HepG2 through in-depth analysis at the genetic level.

[0267] The relative expression levels of PI3K gene in bovine colostrum, yeast β-glucan and the nutritional composition thereof are shown in Table 7.

[0268] Table 7: Relative expression data of PI3K gene in bovine colostrum, yeast β-glucan and nutritional composition thereof

[0269]

[0270] Wherein, “—” indicates no addition or no proportional relationship, “**” indicates P < 0.01, and “***” indicates P < 0.001.

[0271] As shown in Table 7, compared with the model control group, the exemplary nutritional composition can restore the normal function of the PI3K signaling pathway, improve the signaling efficiency of insulin in HepG2 cells, and increase the uptake and utilization of glucose, and is expected to be used to reverse insulin resistance and restore the normal metabolic function of cells. In addition, the inventors surprisingly found that when bovine colostrum and yeast β-glucan are used in combination, they have a synergistic effect on restoring the normal PI3K signaling pathway. In particular, according to cell experiment Example 4, it can be seen that:

[0272] In terms of the components and dosages used, Example 4 is equivalent to the combination of cell experiment comparative examples 1 and 6. Compared with the model control group, comparative examples 1 and 6 increased the relative expression of the PI3K gene by 0.15 and 0.33, respectively, while cell experiment Example 4 increased the relative expression of the PI3K gene by 0.53, which is greater than the sum of the first two, 0.48, and also greater than each of the first two.

[0273] Test Example 4: Results of the lipid-lowering experiment

[0274] 1. Determination of triglyceride content in cell models

[0275] A HepG2 cell hyperlipidemia model with triglyceride accumulation was constructed by inducing oleic acid, and simvastatin was used as a positive control drug. This test case will investigate whether the early intervention treatment of the nutritional composition can effectively improve the accumulation of triglycerides, thereby alleviating hyperlipidemia. The triglyceride accumulation of cells treated with bovine colostrum, yeast β-glucan and their nutritional composition is shown in Table 8.

[0276] Table 8: Triglyceride accumulation in cells treated with bovine colostrum, yeast β-glucan and their nutritional composition

[0277]

[0278] Wherein, “—” indicates no addition or no proportional relationship, “**” indicates P < 0.01, and “***” indicates P < 0.001.

[0279] Triglycerides are formed by the esterification of glycerol and fatty acids and are the main component of blood lipids. Increased triglyceride accumulation in tissues and cells is closely related to obesity and fatty liver. The triglyceride detection kit can accurately measure the triglyceride content in tissue cells. The detection is corrected by protein. The higher the measured value, the higher the triglyceride level, and the lower the measured value, the lower the triglyceride content.

[0280] As shown in Table 8, the sample treatment results show that compared with the model control group, the combination of yeast β-glucan and bovine colostrum can significantly reduce OA-induced lipid deposition in HepG2 hepatocytes. This indicates that both ingredients are helpful in improving blood lipids.

[0281] In terms of the components and dosages used, Example 4 is equivalent to the combination of cell experiment comparative examples 1 and 6. Compared with the model control group, comparative examples 1 and 6 reduced the intracellular triglyceride content by 12.03 and 2.6, respectively, while Example 4 reduced the intracellular triglyceride content by 18.21, which is greater than the sum of the first two by 14.63 and greater than each of the first two.

[0282] Example 5 is equivalent to the combination of cell experiment comparative examples 3 and 7. Compared with the model control group, comparative examples 3 and 7 reduce the intracellular triglyceride content by 7.75 and 1.9, respectively, while example 5 reduces the intracellular triglyceride content by 26.96, which is greater than the sum of the first two by 9.65 and greater than each of the first two.

[0283] Example 8 is equivalent to the combination of cell experiment comparative examples 3 and 6. Compared with the model control group, comparative examples 3 and 6 reduced the intracellular triglyceride content by 7.75 and 2.6, respectively, while example 8 reduced the intracellular triglyceride content by 16.14, which is greater than the sum of the first two by 10.35 and greater than each of the first two.

[0284] 2. Lipoprotein lipase (LPL) activity detection

[0285] In order to further evaluate the effects of nutrients and their compositions on the hyperlipidemia cell model, this test example measured the LPL enzyme activity of cells after different treatments. The LPL enzyme activity of cells treated with bovine colostrum, yeast β-glucan and their nutrient compositions is shown in Table 9.

[0286] Table 9: LPL activity data of cells treated with bovine colostrum, yeast β-glucan and their nutritional composition

[0287]

[0288] Wherein, “—” indicates no addition or no proportional relationship, “*” indicates P < 0.05, and “***” indicates P < 0.001.

[0289] The experimental results (Table 9) show that low doses of bovine colostrum, high doses of yeast β-glucan and certain specific nutritional compositions can significantly restore the LPL activity of cells. In terms of the components and dosages used, Example 1 is equivalent to the combination of cell experimental comparative examples 2 and 5. Compared with the model control group, comparative examples 2 and 5 increased the LPL activity of cells by -0.001 and 0.006, while Example 1 increased the LPL activity of cells by 0.007, which is greater than the sum of the first two 0.005.

[0290] Example 2 is equivalent to the combination of cell experiment comparative examples 2 and 6. Compared with the model control group, comparative examples 2 and 6 increased the LPL activity of cells by -0.001 and 0.018, while example 1 increased the LPL activity of cells by 0.04, which is greater than the sum of the first two 0.017.

[0291] Example 7 is equivalent to the combination of cell experiment comparative examples 4 and 5. Compared with the model control group, comparative examples 4 and 5 increased the LPL activity of cells by 0.008 and 0.006, respectively, while Example 1 increased the LPL activity of cells by 0.016, which is greater than the sum of the first two, 0.014.

[0292] 3. Analysis of PPAR-α gene expression

[0293] PPAR-α (peroxisome proliferator-activated receptor-α) is a gene that plays a key role in lipid metabolism. Oleic acid, as an unsaturated fatty acid, can induce a hyperlipidemic phenotype in HepG2 cells and activate lipid metabolism pathways. In oleic acid-induced hyperlipidemic HepG2 cells, the expression of PPAR-α is crucial. The activation of PPAR-α promotes lipid degradation. By studying the expression of PPAR-α in oleic acid-induced hyperlipidemic HepG2 cells intervened by nutritional compositions, we can better analyze its mechanism for alleviating hyperlipidemic symptoms.

[0294] The relative expression levels of PPAR-α gene in bovine colostrum, yeast β-glucan and the nutritional composition thereof are shown in Table 10.

[0295] Table 10: PPAR-α gene relative expression data of bovine colostrum, yeast β-glucan and nutritional composition thereof

[0296]

[0297] Wherein, “—” indicates no addition or no proportional relationship, “*” indicates P < 0.05, and “***” indicates P < 0.001.

[0298] As shown in Table 10, compared with the model control group, the exemplary nutritional composition can restore the normal function of the PPAR-α signaling pathway, improve lipid metabolism, and maintain the homeostasis of intracellular lipids. In addition, the inventors surprisingly found that when bovine colostrum and yeast β-glucan are used in combination, they have a synergistic effect on restoring the normal function of the PPAR-α signaling pathway. In particular, according to cell experiment examples 1, 3, 5, 6, and 7, it can be seen that:

[0299] In terms of the components and dosages used, Example 1 is equivalent to the combination of Cell Experiment Comparative Examples 2 and 5. Compared with the model control group, Comparative Examples 2 and 5 increased the relative expression of PPAR-α gene by 0.20 and 0.04, respectively, while Cell Experiment Example 1 increased the relative expression of PPAR-α gene by 1.07, which is greater than the sum of the first two, 0.24, and greater than each of the first two.

[0300] In terms of the components and dosages used, Example 3 is equivalent to the combination of cell experiment comparative examples 4 and 7. Compared with the model control group, comparative examples 4 and 7 increased the relative expression of PPAR-α gene by 0.19 and 0.23, respectively, while cell experiment Example 3 increased the relative expression of PPAR-α gene by 1.03, which is greater than the sum of the first two by 0.42 and greater than each of the first two.

[0301] The same conclusion can be drawn from Examples 5, 6 and 7.

[0302] It can be seen that the present invention provides the effects of bovine colostrum and yeast β-glucan composition on lowering blood sugar and blood lipids, especially on improving PA-induced insulin resistance and OA-induced lipid deposition, which provides new ideas for the development of functional foods in the future. Bovine colostrum and yeast β-glucan have broad prospects in improving blood sugar and blood lipids in the body. The research of the present invention shows that in an in vitro model, HepG2 cells treated with a combination of yeast β-glucan and bovine colostrum have significantly improved insulin resistance and lipid deposition, and there is a good synergistic effect between the components.

[0303] It should be noted that, although the technical solution of the present invention is introduced with specific examples, those skilled in the art will appreciate that the present invention should not be limited thereto.

[0304] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. A nutritional composition that helps maintain healthy levels of blood lipids and / or blood sugar, characterized in that: The nutritional composition comprises the following essential components: a colostrum component and a β-glucan component; Furthermore, in the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is (200-0.1):(0.1-100).

2. The nutritional composition according to claim 1, characterized in that In the nutritional composition, the mass ratio of the colostrum component to the β-glucan component is (150-0.5):(0.5-100).

3. The nutritional composition according to claim 1 or 2, characterized in that The colostrum component includes colostrum and / or colostrum powder, and optionally, the colostrum is derived from at least one of cattle, sheep, horses and camels; and / or The β-glucan component includes one or more β-glucans derived from plants or fungi.

4. The nutritional composition according to any one of claims 1 to 3, characterized in that The β-glucan includes yeast β-glucan.

5. A food, characterized in that: The food contains or uses the nutritional composition according to any one of claims 1 to 4.

6. The food according to claim 5, characterized in that The food is a nutritional food, a functional food or a health product.

7. The food according to claim 5 or 6, characterized in that The food includes pasta, beverages, reconstituted food, baked cakes, sauces or functional nutritional supplements.

8. Use of a composition containing two essential components, colostrum and β-glucan, in preparing a nutritional composition that helps maintain healthy blood lipid and / or blood sugar levels.

9. Use of a composition containing two essential components, colostrum and β-glucan, in preparing food that helps maintain healthy blood lipid and / or blood sugar levels.

10. The use according to claim 8 or 9, characterized in that The nutritional composition or the food inhibits the activity of α-glucosidase, alleviates insulin resistance, improves insulin sensitivity, restores glucose consumption capacity and / or increases the expression of gene PI3K; and / or The nutritional composition or the food reduces lipid deposition in liver cells, increases lipoprotein lipase activity and / or enhances PPAR-α gene expression.

Images